Patient Services offers pharmaceutical companies a tremendous opportunity—for those willing to invest in the right places and let patients know about them in the right way. We surveyed 200+ patient services executives in the pharma industry to understand where their companies are in developing patient services and where they intend to go over the next two years and contrasts that with patients told us they want, value and expect from patient services.
Our survey covered seven therapeutic areas: heart, lungs, brain, immune systems, bones, hormone/metabolism, and cancer. And guess what? Our study revealed that the future of patient services is bright—for both pharmaceutical companies and patients.
This research report is intended to help pharmaceutical companies’ hone in on the services that present the highest potential—for them and the people who use their therapeutics—so they can take a leadership role in shaping this rapidly evolving market and prepare for the shift from delivering products to delivering better patient and health system outcomes.
9 of the top 10 services offered by companies are driving above average business impact.
companies are planning to invest in patient engagement technologies over the next 18 months.
Top three ways to make patients aware of services.
Patient Outreach, Reminders and Scheduling:
Valued by 85%
Expected increase by 55%
Valued by 79%
Expected increase by 68%
Valued by 79%
Expected increase by 54%
Pharmaceutical Patient Services Executives asked to benchmark current and anticipated activities and investment in patient services:
100 based in the US
103 based in Europe